Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT: NCT02608216 · ACTIVE_NOT_RECRUITING

NCT IDNCT02608216
StatusACTIVE_NOT_RECRUITING
SponsorUniversity of Pennsylvania (OTHER)
First posted
Last updated

Brief Summary

In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑